Quarterly report pursuant to Section 13 or 15(d)

Grant Revenue (Details)

v3.21.2
Grant Revenue (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 64 Months Ended
Jan. 07, 2020
Dec. 31, 2019
Oct. 31, 2017
May 31, 2017
Jun. 30, 2016
May 31, 2016
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Grant Revenue                      
Revenue             $ 501,567 $ 849,732 $ 1,499,706 $ 2,344,777  
Grant revenue | Maximum                      
Grant Revenue                      
Amount awarded from NIH grant $ 224,713                    
Pelican Therapeutics, Inc. | Grant revenue                      
Grant Revenue                      
Amount awarded from CPRIT grant           $ 15,200,000          
Revenue               $ 0   $ 0 $ 14,600,000
Remaining grant amount receivable             1,500,000   1,500,000   1,500,000
Amount the company is required to match of each dollar of grant             0.50   0.50   0.50
Threshold amount for match of grant             1.00   1.00   1.00
Contribution to be made by Pelican             $ 7,600,000   $ 7,600,000   $ 7,600,000
Pelican Therapeutics, Inc. | Grant revenue | Maximum                      
Grant Revenue                      
Amount awarded from CPRIT grant         $ 15,200,000            
Royalty percentage after threshold is met                 1.00%    
Pelican Therapeutics, Inc. | Grant revenue | Tranche 1                      
Grant Revenue                      
Revenue       $ 1,800,000              
Pelican Therapeutics, Inc. | Grant revenue | Tranche 2                      
Grant Revenue                      
Revenue     $ 6,500,000                
Pelican Therapeutics, Inc. | Grant revenue | Tranche 3                      
Grant Revenue                      
Revenue   $ 5,400,000